Hemophilia A and B patients who use marstacimab have less annualized bleeding.

Published Date: 11 Jan 2024

Pfizer reports that in hemophilia A and B patients without inhibitors, marstacimab decreased the annualized bleeding rate (ABR) by 35 percent and nearly 92 percent, respectively, in comparison to routine prophylaxis and on-demand treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot